Short Interest in ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) Declines By 85.8%

ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) saw a significant decline in short interest in the month of June. As of June 30th, there was short interest totalling 38,300 shares, a decline of 85.8% from the June 15th total of 269,900 shares. Approximately 1.4% of the shares of the company are sold short. Based on an average daily trading volume, of 51,700 shares, the short-interest ratio is presently 0.7 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $72.00 price target on shares of ASLAN Pharmaceuticals in a research report on Friday, May 3rd.

ASLAN Pharmaceuticals Stock Up 7.9 %

ASLN opened at $2.47 on Friday. The business’s 50 day moving average is $3.06 and its two-hundred day moving average is $4.13. ASLAN Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $25.44. The firm has a market cap of $5.05 million, a price-to-earnings ratio of -0.90 and a beta of 1.40.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last announced its earnings results on Thursday, May 9th. The company reported ($10.32) earnings per share for the quarter, missing the consensus estimate of ($5.44) by ($4.88). Equities analysts expect that ASLAN Pharmaceuticals will post -20.36 EPS for the current fiscal year.

ASLAN Pharmaceuticals Company Profile

ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises eblasakimab (ASLAN004), a monoclonal antibody that targets the IL-13 receptor a1 subunit which is under Phase 2 developed for the treatment of atopic dermatitis and other immunology indications; and farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase currently under Phase 2 clinical trials for the treatment of autoimmune diseases.